{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:30:06Z","timestamp":1791919806828,"version":"4.3.4"},"reference-count":39,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2010,12,15]],"date-time":"2010-12-15T00:00:00Z","timestamp":1292371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:p>The recent health care changes and approval of a generic low-molecular-weight heparin (LMWH) by the US Food and Drug Administration (FDA) merit a review of the facts regarding the new and generic anticoagulants. Fatal hypotension from anaphylactoid type reactions following heparin administration was responsible for more than 149 deaths all over the world. Researchers detected a heparin-like semisynthetic contaminant, over-sulfated chondroitin sulfate (OSCS), that appeared to be intentional. Low-molecular-weight heparins are produced using unfractionated heparin and OSCS has been found in various batches of LMWHs. Some newer anticoagulants are claiming to be free from the need to monitor for therapeutic effect and bleeding risk. Therefore, monitoring assays are not being developed and there is no antidote to reverse bleeding. In addition, there are concerns about reproducibility, product variation, and quality. In conclusion, although the generic LMWHs and newer anticoagulants may appear to be effective for qualified indications, their safety remains to be a concern.<\/jats:p>","DOI":"10.1177\/1076029610387128","type":"journal-article","created":{"date-parts":[[2010,12,15]],"date-time":"2010-12-15T20:33:37Z","timestamp":1292445217000},"page":"136-139","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["New and Generic Anticoagulants and Biosimilars: Safety Considerations"],"prefix":"10.1177","volume":"17","author":[{"given":"Evi","family":"Kalodiki","sequence":"first","affiliation":[{"name":"Vascular Surgery Department, Ealing Hospital and Imperial College London, SW7 2AZ, UK, Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Centre, Maywood, IL, USA,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawed","family":"Fareed","sequence":"additional","affiliation":[{"name":"Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Centre, Maywood, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2010,12,15]]},"reference":[{"key":"atypb1","unstructured":"http:\/\/cardiobrief.org\/2010\/07\/23\/fda-approves-first-generic-low-molecular-weight-heparin\/ . Accessed August 7, 2010."},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200721060-00003"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1159\/000085690"},{"issue":"6","key":"atypb4","first-page":"457","volume":"27","author":"Fareed J.","year":"2008","journal-title":"Int Angiol"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0803200"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1407"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806450"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1177\/1076029609338710"},{"issue":"2","key":"atypb9","first-page":"193","volume":"29","author":"Kalodiki E.","year":"2010","journal-title":"Int Angiol"},{"key":"atypb10","unstructured":"http:\/\/www.natfonline.org\/docs\/Consensus%20Report%20Draft%20v6.pdf. Consensus meeting: call to action on issues of complex biologics and patient safety. Accessed July 31, 2010."},{"key":"atypb11","unstructured":"http:\/\/www.sasat.org\/. Accessed July 31, 2010."},{"key":"atypb12","unstructured":"http:\/\/www.i.u.angiology.org\/news.php. Accessed July 28, 2010."},{"key":"atypb13","unstructured":"http:\/\/www.iua2010.com.ar\/ Accessed 25 Oct, 2010."},{"key":"atypb14","unstructured":"http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm207506.htm. Accessed July 28, 2010."},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.8.62S.34594"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2004.09.005"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1177\/1076029608319881"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1066025"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2005.tb00176.x"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L194"},{"issue":"2","key":"atypb21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1055\/s-0037-1619652","volume":"25","author":"Hartmann A.","year":"2005","journal-title":"Hamostaseologie"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.2174\/092986709788803105"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2008.00942.x"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-008-9015-x"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-982080"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1177\/1076029606291434"},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528040-00005"},{"key":"atypb28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2006.00594.x"},{"key":"atypb29","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl475"},{"issue":"20","key":"atypb30","first-page":"2802","volume":"125","author":"Eritsland J.","year":"2005","journal-title":"Tidsskr Nor Laegeforen"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1177\/1076029609332727"},{"key":"atypb32","unstructured":"http:\/\/www.i.u.angiology.org\/news_singola.php?idsingnews=7 . Accessed July 31, 2010."},{"key":"atypb33","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1948"},{"key":"atypb34","unstructured":"http:\/\/www.emea.europa.eu\/pdfs\/human\/biosimilar\/11826407enfin.pdf . Accessed August 7, 2010."},{"key":"atypb35","unstructured":"http:\/\/www.europharmatoday.com\/2009\/06\/generic-lovenox-ineu-will-require-clinical-data-shrinking-sandozs-opportunity-html . Accessed July 31, 2010."},{"key":"atypb36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.07.017"},{"key":"atypb37","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181ae6dbe"},{"key":"atypb38","unstructured":"Spring S. US FDA. Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation. 2009. Accessed July 28, 2010."},{"key":"atypb39","unstructured":"http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/05\/briefing\/2005-4137B1_07_Nomenclature.pdf. Accessed 5 September, 2010."}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1076029610387128","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1076029610387128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:01:04Z","timestamp":1777384864000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1076029610387128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,15]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1177\/1076029610387128"],"URL":"https:\/\/doi.org\/10.1177\/1076029610387128","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,15]]}}}